Announcement
DHL Global Forwarding has expanded its healthcare cold chain network with six new dedicated, bi-directional corridors connecting Europe and North America to pharmaceutical and healthcare hubs in Asia, the company announced on October 12 (Source: DHL Group press release; Supply Chain Dive).
The six routes extend the DHL Health Logistics Cold Chain Network, which the company has been building out through 2026 as part of a €2 billion strategic investment in its life sciences and healthcare logistics business (Source: DHL Group). The new corridors are designed to give temperature-sensitive healthcare shippers more routing options and to strengthen links between major pharmaceutical manufacturing, research and distribution hubs (Source: The Logistic News).
Which routes were added
On the North American side, the network adds three corridors out of DHL's Cincinnati hub (CVG): Cincinnati to Singapore (SIN), Cincinnati to Tokyo Narita (NRT), and Cincinnati to Seoul Incheon (ICN). On the European side, the expansion adds Liege to Shanghai, Brussels to Shanghai, and Brussels to Singapore (Source: Supply Chain Dive; The Logistic News). The routes serve four Asian pharmaceutical hubs — Shanghai, Singapore, Tokyo Narita and Seoul Incheon — using temperature-controlled air freight capacity across DHL's network, with Boeing freighters among the equipment deployed on the lanes (Source: EuropaWire).
The expansion follows the introduction of a Brussels–Cincinnati corridor earlier in 2026, which the company described as the first step in extending its dedicated cold chain across the transatlantic route (Source: EuropaWire; DHL Group). DHL has also pointed to further healthcare logistics investment in Singapore, Cincinnati and Indianapolis as part of the same buildout (Source: EuropaWire).
Why the network is expanding now
DHL's stated priority markets for the healthcare expansion include India, Singapore, Japan, South Korea, Brazil, the United States, Germany and Ireland, with each route designed to meet strict regulatory requirements for the transport of medicines, vaccines and advanced therapies (Source: DHL Group Japan release). The company's Life Sciences & Healthcare unit has been positioning temperature-controlled air freight as a higher-value alternative to ocean shipping for time- and temperature-sensitive products such as biologics, cell and gene therapies, and clinical trial materials.
The October move is the latest installment of a strategy that DHL laid out in February 2026, when it announced a major step to strengthen its Life Sciences & Healthcare logistics capabilities through an expanded dedicated airfreight cold chain network. The company described the network as "another core element" of its €2 billion strategic investment in DHL Health Logistics, built around full end-to-end visibility for temperature-sensitive medicines, vaccines, pharmaceutical products and cell and gene therapies (Source: DHL Group February 2026 release). The operating layer of that network combines GxP-compliant temperature-controlled transportation with proactive intervention in the event of an excursion, plus the LifeTrack cold-chain tracking application and supply chain risk analytics (Source: DHL US pharmaceutical services page).
In a February 2026 announcement that set the stage for this expansion, DHL said it was reshaping how temperature-sensitive medicines, vaccines, pharmaceutical products and cell and gene therapies move globally, with full end-to-end visibility as a core promise of the network (Source: DHL Group February 2026 release). The company's GxP-compliant cold chain offering includes the LifeTrack temperature-monitoring application and supply chain risk analytics, as well as proactive intervention when temperature excursions occur (Source: DHL US pharmaceutical services page). DHL's expanded footprint also includes continued healthcare logistics investment in Singapore, Cincinnati and Indianapolis, which the company has identified as strategic nodes for the Life Sciences & Healthcare business (Source: EuropaWire).
Industry context
The corridor expansion comes as pharmaceutical logistics providers compete for a share of the fast-growing biologics and cell therapy trade between the US, Europe and Asia. Asia's role as both a manufacturing base and a consumption market for advanced medicines has pushed forwarders to build dedicated, airport-to-airport temperature-controlled capacity rather than relying on general cargo space with add-on cooling. Contract logistics players and air forwarders alike have been investing in pharma-grade hubs, validated packaging and 24/7 monitoring capabilities, and the competition for pharma shippers' lane-level business has intensified as manufacturers diversify sourcing and clinical supply chains across regions.
For B2B shippers in the healthcare space, the practical effect of the six new corridors is more predictable capacity on the Asia lanes, particularly out of the Cincinnati hub, which is DHL's largest US gateway for time-critical freight. The bi-directional design also matters commercially: it allows the airline economics of the routes to balance import and export volumes, which is a precondition for keeping dedicated cold chain capacity profitable on routes with uneven trade flows. For shippers, more dedicated corridors mean more routing options to compare on transit time, temperature reliability and price, and more leverage in annual logistics contract negotiations (Source: The Logistic News).
No pricing details were disclosed, and DHL has not said when each corridor will reach full operating capacity. For shippers, the immediate action items are the same as for any network change: verify that the new lanes match their lane-level volume needs, confirm the temperature-controlled service levels (including the 2–8°C and cryogenic ranges where applicable), and re-bid contracts where the additional routing options create negotiating leverage. The expansion also reinforces a broader trend for procurement teams: dedicated cold chain capacity is increasingly a differentiated, contracted service rather than a standard add-on to general airfreight, and shippers that lock in corridor-level agreements early will have an advantage when peak-season capacity tightens (Source: DHL Group; Supply Chain Dive).
